Oppenheimer & Co. Inc. Buys 35,823 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR)

Oppenheimer & Co. Inc. increased its stake in Capricor Therapeutics Inc (NASDAQ:CAPR) by 52.4% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 104,231 shares of the biotechnology company’s stock after acquiring an additional 35,823 shares during the quarter. Oppenheimer & Co. Inc. owned 0.23% of Capricor Therapeutics worth $1,438,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of CAPR. The Manufacturers Life Insurance Company bought a new stake in shares of Capricor Therapeutics in the 3rd quarter valued at $161,000. FMR LLC acquired a new stake in Capricor Therapeutics in the 3rd quarter valued at $370,000. BNP Paribas Financial Markets grew its position in Capricor Therapeutics by 868.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 17,699 shares of the biotechnology company’s stock valued at $269,000 after purchasing an additional 15,872 shares during the period. Fred Alger Management LLC acquired a new stake in Capricor Therapeutics in the 3rd quarter valued at $399,000. Finally, PFM Health Sciences LP acquired a new stake in Capricor Therapeutics in the 3rd quarter valued at $2,324,000. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Price Performance

CAPR opened at $13.67 on Tuesday. The company has a market capitalization of $621.57 million, a price-to-earnings ratio of -12.90 and a beta of 4.08. The firm’s fifty day moving average price is $14.42 and its two-hundred day moving average price is $13.80. Capricor Therapeutics Inc has a 1 year low of $3.52 and a 1 year high of $23.40.

Analysts Set New Price Targets

CAPR has been the subject of several research reports. HC Wainwright reissued a “buy” rating and issued a $77.00 price target on shares of Capricor Therapeutics in a research report on Thursday, January 2nd. Cantor Fitzgerald lifted their price target on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $34.50.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.